Antiphospholipid syndrome (APS) is an autoimmune disease in which antiphospholipid antibodies (aPLs) are generated. Previous studies show concurrence of APS and thrombotic thrombocytopenic purpura; therefore it is plausible to assume that anti-ADAMTS13 autoantibody is also involved in the pathophysiology of APS. We investigated the clinical significance of ADAMTS13 activity and anti-ADAMTS13 antibody in patients with aPLs. Two hundred and sixteen patients with positive lupus anticoagulant and/or anticardiolipin antibody were included. ADAMTS13 activity and anti-ADAMTS13 antibody were measured using fluorescence resonance energytransfer technology and ELISA, respectively. Reduced ADAMTS13 activity was observed in 40.3% (87/216) of patients with aPLs. Although 33.8% (73/216) of patients were positive for anti-ADAMTS13 antibody, 41 of these 73 patients had normal levels of ADAMTS13 activity. Reduced ADAMTS13 activity was a significant risk factor for thrombotic events. Thrombotic events and age contributed to the reduced level of ADAMTS13 activity. Presence of anti-ADAMTS13 antibody did not show any association with the level of ADAMTS13 activity. Patients with autoimmune diseases tended to show higher levels of anti-ADAMTS13 antibody. Our findings suggest that reduced ADAMTS13 activity is a significant thrombotic risk factor in patients with aPLs irrespective of the presence of anti-ADAMTS13 antibody. Presence of anti-ADAMTS13 antibody is not seen with reduced activity and it tends to be increased in patients with autoimmune diseases. Blood Coagul Fibrinolysis 27:907-912
Introduction
A disintegrin-like and metalloprotease with thrombospondin type I motif, member 13 (ADAMTS13), is a plasma protease that cleaves ultralarge multimers of von Willebrand factor (VWF) released from endothelium into smaller multimers [1] . Thrombotic thrombocytopenic purpura (TTP) is typically seen with severe deficiency of ADAMTS13 that induces accumulation of ultralarge VWF, which in turn results in formation of platelet-rich thrombi within the vessels.
Acquired TTP is considered an autoimmune disease because it frequently shows circulating autoantibodies against ADAMTS13 [2] . Mild to moderate deficiency of ADAMTS13 has been reported in several autoimmune diseases such as systemic lupus erythematosus (SLE) and systemic sclerosis [3] [4] [5] [6] . Moreover, SLE shows increased risk of TTP, probably because of the reduction of ADAMTS13 activity in active SLE that could be stemming from anti-ADAMTS13 autoantibodies [5] .
Antiphospholipid syndrome (APS) is also an autoimmune disease characterized by thrombotic tendency due to antiphospholipid antibodies (aPLs). These antibodies have many target antigens; therefore, it is possible that generation of anti-ADAMTS13 autoantibody and the resulting ADAMTS13 activity contribute to the thrombotic tendency in APS. There are several reports about concurrence of TTP and APS [7, 8] . A study on 46 thrombotic microangiopathic hemolytic anemia cases associated with aPLs found APS in 61% of the patients [9] . Low level of ADAMTS13 activity was also demonstrated in APS patients [10, 11] . However, the data remain uncertain about the frequency of ADAMTS13 deficiency, and the relation between ADAMTS13 activity and thrombotic tendency.
The study measured the ADAMTS13 activity and anti-ADAMTS13 antibody in patients with aPLs and analyzed the thrombotic risk for these markers along with the contributing factors to ADAMTS13 activity and anti-ADAMTS13 antibody.
Materials and methods

Study population and blood sampling
The study was approved by the Institutional Review Board of Seoul National University Hospital. A total of 216 patients who had weakly positive/positive lupus anticoagulant and/or anticardiolipin antibodies were recruited in this study. The characteristics of the patients, including their underlying disorders, are shown in Table 1 . Demographic, clinical, and laboratory data were obtained from the hospital laboratory information system. Thrombosis included deep vein thrombosis, pulmonary thromboembolism, and ischemic stroke. These were objectively documented using Doppler ultrasonography, venography, lung scanning, or magnetic resonance angiography. Twenty healthy normal adults (10 men and 10 women; age 22-28 years), who have no history of hospitalization and autoimmune diseases, were recruited after providing an informed consents to determine the cut-off values for each assay.
Peripheral blood was collected in 3.2% sodium citrate tubes (Becton Dickinson, San Jose, California, USA). It was centrifuged for 15 min at 1550g at room temperature, and the tests were performed within 2 h after blood sampling.
Lupus anticoagulant assay
Lupus anticoagulant was measured using ACL 3000 coagulation analyzer (Instrumentation Laboratory, Milan, Italy). Diluted Russell's viper venom assay (LAC Screen and Confirm kit; Instrumentation Laboratory) and HemosIL silica clotting time test (Instrumentation Laboratory) were performed simultaneously. The results were recorded positive when at least one of these two tests turned out to be positive. The interpretation of results was as follows. Normalized LAC ratio greater than 1.50 was classified as positive and that between 1.17 and 1.50 as weakly positive in diluted Russell's viper venom assay. Normalized Silica Clotting Time ratio greater than 1.50 was interpreted as positive and that between 1.23 and 1.50 as weakly positive.
Anticardiolipin antibody assay
Anticardiolipin antibody (aCL) was detected using the HemosIL AcuStar Anticardiolipin assay IgG, IgM (Instrumentation Laboratory). This test was based on a chemiluminescent two-step immunoassay. Results above 20 U/ml were recorded as positive.
ADAMTS13 activity assay and ADAMTS13 inhibitor assay
The ADAMTS13 activity was determined using LIFE-CODES ATS-13 Activity Assay (Immucor Gamma, Atlanta, Georgia, USA). The assay was based on fluorescence resonance energy transfer (FRET) technology. Cut-off value of ADAMTS13 activity was set as 67% [12] . Anti-ADAMTS13 antibody was measured using TECH-NOZYM ADAMTS-13 INH (Technoclone GmbH, Vienna, Austria). This assay was designed of antigen coating of full-length recombinant ADAMTS13 and the detection antibody of antihuman IgG. This assay was based on ELISA and the values above 15 units/ml were determined as positive.
Statistical analysis
All statistical analyses were performed using SPSS 21.0 (Chicago, Illinois, USA). The frequency of demographic and clinical data was analyzed using chi-square test.
Logistic regression analysis was performed to evaluate the risk factors for thrombosis. Linear regression analysis was carried out to evaluate the contribution of ADAMTS13 activity and anti-ADAMTS13 antibody. Mann-Whitney test was used for comparison of mean values between the two groups. Kruskal-Wallis test were performed for comparison of mean values in more than three groups, and Bonferroni method was applied as the post-hoc analysis. P value less than 0.05 was considered statistically significant in all analyses.
Results
Clinical characteristics of the patients A total of 216 patients (88 men and 128 women) were included in this study ( Table 1 ). The median age was 46.5 (range 1-86) and 99 (45.8%) patients were over the age of 50 years. Forty (18.5%) patients had thrombotic events, including venous thromboembolism in 23 and arterial thromboembolism in 17 patients. Twentynine patients (13.4%) were positive only for lupus anticoagulant and 76 (35.2%) were positive only for aCL. Seventeen (7.9%) patients showed positive results for both lupus anticoagulant and aCL. One hundred and four (48.1%) patients were diagnosed with an autoimmune disease. The autoimmune diseases were mainly SLE (n ¼ 39), presence of autoimmune antibody (n ¼ 24), APS (n ¼ 18), autoimmune encephalitis (n ¼ 8), Sjogren's syndrome (n ¼ 3), Bechet's disease (n ¼ 2), juvenile rheumatoid arthritis (n ¼ 2), neuromyelitis optica (n ¼ 2), autoimmune vasculitis (n ¼ 1), Churg-Strauss syndrome (n ¼ 1), Graves' disease (n ¼ 1), Hashimoto's encephalopathy (n ¼ 1), opsoclonus myoclonus ataxia syndrome (n ¼ 1), and rheumatic fever (n ¼ 1). The frequency of autoimmune diseases was lower in patients with thrombotic events compared to patients without thrombotic events (27.5 vs. 52.8%).
Eighty-seven (40.3%) patients had reduced ADAMTS13 activity. Out of 40 patients with thrombotic events, 25 (62.5%) showed reduced ADAMTS13 activity, and out of 176 patients without thrombotic events, 62 (35.2%) showed reduced ADAMTS13 activity. Seventy-three (33.8%) patients had anti-ADAMTS13 antibody. The positivity of anti-ADAMTS13 antibody was not significantly different between these two groups (32.5 vs. 34.1%). Severe ADAMTS13 deficiency with lower than 10% ADAMTS13 activity was observed in 11 (5.1%) patients. The prevalence of women, autoimmune diseases, and reduced ADAMTS13 activity were significantly different between patients with thrombotic events and patients without thrombotic events (P ¼ 0.017, P ¼ 0.004, and P ¼ 0.002, respectively). There was no statistical difference of ADAMTS13 activity between patients with positive aCL and those with negative aCL. However, patients with positive lupus anticoagulant [median 89.7%; interquartile range (IQR) 63.7-107.2%] tended to show slightly increased ADAMTS13 activity compared with those with negative lupus anticoagulant (median 71.2%; IQR 46.0-92.1%; P ¼ 0.009).
Association between ADAMTS13 activity and anti-ADAMTS13 antibody
Only 32 of 73 patients (43.8%) with anti-ADAMTS13 antibody showed reduced ADAMTS13 activity, whereas the remaining 41 (56.2%) had normal ADAMTS13 activity in spite of anti-ADAMTS13 antibody. Fifty-five of 143 patients (38.5%) with absent anti-ADAMTS13 antibody had reduced ADAMTS13 activity. There was no significant difference in the prevalence of anti-ADAMTS13 antibody between patients with reduced and patients with normal ADAMTS13 activity.
Thrombotic risk of ADAMTS13 activity and anti-ADAMTS13 antibody
The ADAMTS13 activity was significantly decreased in patients (median 73.8%; IQR 50.2-95.7%) compared with normal controls (median 99.7%; IQR 81.6-128.1%; P < 0.001) ( Fig. 1a ). Patients with thrombotic events (median 57.2%; IQR 36.3-81.0%) showed significantly lower ADAMTS13 activity compared to patients without thrombotic events (median 76.2%; IQR 56.9-98.9%; P ¼ 0.013).
Anti-ADAMTS13 antibody level in normal controls (median 3.3 units/ml; IQR 2.4-6.3 units/ml) was significantly lower than patients (median 11.2 units/ml; IQR 8.0-19.2 units/ml; P < 0.001) ( Fig. 1b ). There was no significant difference in anti-ADAMTS13 antibody level between patients without thrombotic events (median Comparison of ADAMTS13 activity and anti-ADAMTS13 antibody levels in normal controls (n ¼ 20), total patients (n ¼ 216), patients without thrombosis (n ¼ 176), and patients with thrombosis (n ¼ 40). (a) ADAMTS13 activity in patients was significantly reduced compared to controls. There was a significant difference in ADAMTS13 activity between patients without thrombosis and patients with thrombosis. (b) Anti-ADAMTS13 antibody in patients was significantly higher than that of controls. Outlier data are not shown. ADAMTS13, a disintegrin-like and metalloprotease with thrombospondin type I motif, member 13. The logistic regression analysis was performed to find out risk factors of thrombosis. Reduced ADAMTS13 activity was a major risk factor of thrombosis [odds ratio (OR) 3.055; 95% confidence interval (CI) 1.477-6.322; P ¼ 0.003] ( Table 2 ). However, presence of anti-ADAMTS13 antibody did not significantly increase the risk of thrombosis. Interestingly, presence of autoimmune diseases had a protective effect for thrombosis (OR 0.308; 95% CI 0.136-0.701; P ¼ 0.005).
Contributing factors of ADAMTS13 activity and anti-ADAMTS13 antibody
To find the factors associated with ADAMTS13 activity and anti-ADAMTS13 antibody, linear regression analyses were performed (Table 3 ). In univariable regression, age, female sex, and thrombosis were significantly related to ADAMTS13 activity (P < 0.001, P ¼ 0.031, and P ¼ 0.003, respectively). However, anti-ADAMTS13 antibody did not show any relation to the ADAMTS13 activity. Multivariable regression analysis revealed that age and thrombosis independently influence the ADAMTS13 activity (P < 0.001 and P ¼ 0.019). When anti-ADAMTS13 antibody was considered as a dependent variable, the presence of autoimmune diseases significantly affected the antibody level in univariable regression analysis (P ¼ 0.005). In multivariable regression, autoimmune disease was excluded from independent variables because of its multicollinearity with anti-ADAMTS13 antibody. The presence of autoimmune diseases was found to be related to anti-ADAMTS13 antibody in the multivariable regression analysis (P ¼ 0.005).
Levels of ADAMTS13 activity and anti-ADAMTS13 antibody in patients with autoimmune diseases
Patients without autoimmune diseases were not different for ADAMTS13 activity (median 70.7%; IQR 50.2-94.6%) compared to patients with autoimmune diseases (median 77.0%; IQR 50.0-98.9%) ( Fig. 2a ). However, patients with autoimmune diseases (median 14.9 units/ml; IQR 9.1-23.1 units/ml) had higher anti-ADAMTS13 antibody levels compared to patients without autoimmune disease (median 9.8 units/ml; IQR 7.0-13.7 units/ml; P < 0.001) (Fig. 2b ).
Discussion
Our study found reduced ADAMTS13 activity in 40.3% (87/216) of patients with aPLs. Although 33.8% (73/217) of patients were positive for anti-ADAMTS13 antibody, a substantial portion of patients had normal levels of ADAMTS13 activity. Reduced ADAMTS13 activity was a significant risk factor for thrombotic events. However, the presence of autoimmune disease was rather a significant protective factor for thrombotic events in our study. The thrombotic event and age were independently associated with the ADAMTS13 activity levels. Presence of anti-ADAMTS13 antibody was not associated with ADAMTS13 activity level. Patients with autoimmune diseases showed higher levels of anti-ADAMTS13 antibody and the presence of autoimmune diseases was significantly associated with the anti-ADAMTS13 antibody level.
Although severe deficiency of ADAMTS13 activity is a characteristic finding in TTP, its reduced activity is also found in several clinical conditions such as SLE, scleroderma, and APS. There are several studies on the level of ADAMTS13 activity in patients with aPLs [10, 11] . Austin et al. [10] found that 33% of their patients had reduced ADAMTS13 activity, which was measured by collagen-binding assay. This is slightly below our finding of 40.3%, which was measured by the FRET method. This difference could be partially due to the method of assay [13] . Rieger et al. [11] reported that the levels of ADAMTS13 activity range from 32 to 114% in 55 APS patients, whereas Kobayashi et al. [14] reported no reduction of ADAMTS13 activity in APS. In all these studies, the clinical significance of reduced ADAMTS13 activity remained undetermined. Our findings show that reduced ADAMTS13 activity is independently associated with the risk of thrombosis. It is plausible to assume that the reduced ADAMTS13 activity increases the thrombotic tendency by increasing the circulating levels of VWF multimers via decreasing the proteolytic activity of ADAMTS13 on VWF multimers. The potential cause of thrombotic events cannot be demonstrated in our study because we did not measure VWF multimers; yet, there is a study that shows a tendency for high levels of larger VWF multimers in some patients with reduced ADAMTS13 activity [10] , which means that reduced ADAMTS13 activity could be considered as a potential cause of increased thrombotic tendency in our study.
The ADAMTS13 activity is usually decreased in acquired TTP because of autoantibodies against ADAMTS13 [15] . The neutralizing antibodies block the proteolytic activity of ADAMTS13 on VWF, whereas non-neutralizing antibodies can increase ADAMTS13 clearance from circulation or interfere with the ADAMTS13 binding with other cells or plasma proteins [16] . Our ELISA assay can detect both neutralizing and non-neutralizing IgG antibodies [17] . Interestingly, presence of anti-ADAMTS13 antibody had no significant association with reduced ADAMTS13 activity. Several potential mechanisms of decreased ADAMTS13 level can be speculated apart from anti-ADAMTS13 antibody.
ADAMTS13 activity can be inhibited by inflammatory cytokine interleukin (IL)-6 or cleaved by protease released from neutrophils partly [18] .
In our linear regression analysis, the presence of autoimmune diseases was found to be associated with increased antibody levels. Likewise, patients with autoimmune diseases showed higher levels of anti-ADAMTS13 antibody. Therefore, the autoimmune disease, by itself, increases the detection of anti-ADAMTS13 antibody. Our findings are in accordance with previous studies that show anti-ADAMTS13 antibody increases in autoimmune diseases such as APS and SLE [5, 10, 11, 19] .
The presence of anti-ADAMTS13 antibody was found to be a protective factor for thrombotic events in our population. Because we recruited a large proportion of patients with autoimmune diseases without thrombotic event compared to those with thrombotic event, we could analyze the autoimmune disease as a factor against the thrombotic risk. Autoimmune disease was not found as a protective factor for thrombosis in the general population.
We found that ADAMTS13 activity was associated with age, sex, and thrombotic events. The value of beta for age was À0.605 (Table 3) , reflecting that ADAMTS13 activity is decreased by 0.605% each year. This finding is in accordance with another study [20] that showed age relationship with ADAMTS13 in the healthy population. Female sex was found to be significantly influencing the ADAMTS13 activity in univariable regression analysis, but multivariable regression disproved the significance of female sex, suggesting that the statistics is unevenly influenced by proportional distribution of women in subpopulations of our study. Finally, the presence of thrombotic events was independently associated with reduced ADAMTS13 activity. Once again, this confirmed Comparison of ADAMTS13 activity and anti-ADAMTS13 antibody levels between patients without autoimmune diseases (n ¼ 112) and patients with autoimmune diseases (n ¼ 104). (a) ADAMTS13 activity was not significantly different between the two groups. (b) Anti-ADAMTS13 antibody in patients with autoimmune disease was significantly higher than that of patients without autoimmune diseases. Outlier data are not shown. ADAMTS13, a disintegrin-like and metalloprotease with thrombospondin type I motif, member 13.
that reduced ADAMTS13 activity is a significant thrombotic risk factor in APS.
The study has several limitations. First, because our study was designed as a case-control study, we could not investigate a causal relationship between ADAMTS13 activity and thrombotic events. A prospective study is required to explore whether ADAMTS13 activity is the cause or the effect of the thrombotic event.
Second, VWF multimer level is required to verify the prothrombotic potential of reduced ADAMTS13 activity. Although we did not measure the multimer concentration, our data demonstrated the significant association between ADAMTS13 activity and thrombotic events.
Our findings suggest that reduced ADAMTS13 activity is a significant thrombotic risk factor in patients with aPLs irrespective of the existence of anti-ADAMTS13 antibody. The presence of anti-ADAMTS13 antibody is related to autoimmune disease. However, it accounts for only part of the reduced ADAMTS13 activity.
